Pancreatic Cancer

Pancreatic cancer is a devastating disease characterized by the uncontrolled growth of cells in the pancreas, a vital organ located behind the stomach. It is a formidable challenge in the field of oncology due to its aggressive nature, late-stage diagnosis, and limited therapeutic options. As a pioneer in the gastrointestinal cancer field, Alfa Cytology provides a complete solution for pancreatic cancer.

Introduction to Pancreatic Cancer

Pancreatic cancer occurs when normal cells in the pancreas undergo genetic mutations that cause them to grow and divide uncontrollably. These abnormal cells accumulate and form tumors in the pancreas, disrupting its normal structure and function. The pancreas has two main types of cells: 

The majority of pancreatic cancers, approximately 95%, arise from the exocrine cells and are called pancreatic ductal adenocarcinomas (PDAC).

Pathogenesis of Pancreatic Cancer

The pathogenesis of pancreatic cancer is a complex interplay of genetic, environmental, and lifestyle factors. The majority of pancreatic cancers arise from the ductal epithelial cells of the pancreas and are classified as pancreatic ductal adenocarcinoma (PDAC). Several key genetic alterations have been identified in PDAC, including mutations in the KRAS, TP53, CDKN2A, and SMAD4 genes.

Fig.1 Mechanisms of pancreatic cancer pathogenesis. (Wood, L. D., et al., 2022)

Mutations in the KRAS gene are particularly prevalent and occur early in the development of pancreatic cancer. The mutant KRAS protein drives uncontrolled cell proliferation and survival, contributing to the aggressive nature of the disease. TP53 mutations, on the other hand, disrupt the tumor suppressor function of the p53 protein, allowing cells with damaged DNA to evade cell death and promote tumor growth.

Therapy Development for Pancreatic Cancer

The pancreatic cancer treatment and diagnostics market is very large. The global pancreatic cancer treatment and diagnostics market size is expected to reach USD 60 billion by 2024, at a CAGR of 18.00%, and USD 360 billion by 2036.

Pancreatic cancer pipeline report is a robust space with 40+ active players working to develop 50+ pipeline therapies for pancreatic cancer. Promising pancreatic ductal adenocarcinoma pipeline therapies in phase III trials stages of development include: 

Our Services

This surge in market size underscores the increasing demand for effective and innovative therapy solutions for pancreatic cancer. Alfa Cytology is devoted to developing more effective and personalized therapy for pancreatic cancer. We provide one-stop solutions for pancreatic cancer, including but not limited to the following.

Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for pancreatic cancer. For more information about our pancreatic cancer research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.

For research use only.